Poolbeg Pharma appoints Brendan Buckley as an Independent Non-Executive Director

Poolbeg Pharma plc (LON:POLB), a leading biopharmaceutical company focusing on infectious and prevalent diseases with a high unmet medical need, has announced the appointment of Brendan Buckley as an Independent Non-Executive Director of the Company with immediate effect. Brendan will also replace Cathal Friel as a member of the Remuneration Committee.

Professor Buckley is the former Chief Medical Officer of ICON plc, a medical graduate of University College Cork and a doctoral graduate in Biochemistry in the Faculty of Medicine at Oxford University. Prof Buckley has advised Poolbeg since inception and has deep experience in metabolic diseases including over 40 years’ experience in clinical practice as a Consultant Physician in endocrinology, diabetes and in academic clinical pharmacology. Brendan was a member of the Board of Directors of the Irish Medicines Board (now the Health Products Regulatory Authority), chairing its statutory Advisory Committee for Human Medicines. He was also a member of the European Medicines Agency Committee for Orphan Medicinal Products (COMP) and of the European Medicines Agency Scientific Advisory Committee on diabetes and metabolism. Brendan has published over 150 scientific papers, mainly on metabolic disease, as well as the recent key opinion-leading book ‘Re-Engineering Clinical Trials’.

Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said: “We are delighted to have Brendan join the Board of Directors. His significant contribution to Poolbeg during his role as a member of the Scientific Advisory Board, and his considerable industry experience will be of tremendous benefit as we continue to pursue our goal of becoming a one-stop-shop for pharma and biotechs seeking products to in-license.”

Brendan Buckley, Non-Executive Director of Poolbeg Pharma, said:” I am honoured to be joining the Board at this exciting time of the Company’s development. Poolbeg has a unique model and pipeline and I look forward to working alongside such a strong Management Team targeting a number of growing markets.”

Regulatory Disclosures

The following disclosures are required under Schedule Two, paragraph (g) of the AIM Rules for Companies:

Mr Brendan Mary Buckley, aged 73, has held the following directorships and/or partnerships in the past five years:

Current directorships:

·      hVIVO plc

·      FIGHTING BLINDNESS

·      DS BIOPHARMA LIMITED

·      Afimmune Limited

·      Open Orphan DAC

·      Imutex Ltd

Past directorships:

·      BREAKTHROUGH CANCER RESEARCH

·      Alliance for Clinical Research Excellence and Safety Inc.

Mr Buckley has a beneficial interest in 2,631,474 ordinary shares of the Company representing approximately 0.5 per cent. of the total voting rights.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Poolbeg Pharma

More articles like this

AI revolutionises drug discovery and pharmaceutical research

The future of drug discovery and pharmaceutical research is being reshaped by artificial intelligence (AI), heralding a new era of speed, efficiency, and precision. AI’s potential to accelerate drug development, from molecular prediction to optimised design

Poolbeg Pharma relocates to new London headquarters at 40 Bank Street

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the Company has changed its registered address to 40 Bank Street,

Innovative approaches at Poolbeg Pharma

Poolbeg Pharma plc is dedicated to the development and commercialisation of innovative medicines, particularly those targeting diseases with high unmet medical needs, including rare and orphan diseases. The company’s strategy revolves around developing its promising clinical

GLP-1 receptor agonists transform diabetes treatment

GLP-1 (glucagon-like peptide-1) and its receptor agonists (GLP-1RAs) have emerged as a groundbreaking class of drugs in diabetes management, particularly due to their impressive efficacy in reducing obesity, a key factor in type 2 diabetes. Jeremy

AI revolutionising the pharmaceutical industry

The rapid advancement of artificial intelligence (AI) is making significant strides in the pharmaceutical sector. Since its inception, this industry has embraced AI and machine learning, continuing its legacy of innovation. The integration of these technologies

Poolbeg Pharma publishes Annual Report and AGM Notice

Poolbeg Pharma plc (LON: POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has confirmed that the Company’s Annual Report and Accounts for the period ended

Poolbeg Pharma expands treatment into new markets

Poolbeg Pharma said it had made progress last year in expanding its treatments into new markets, with significant pipeline advancements and strategic deals. The company said it had made a strategic expansion into the treatment of

Poolbeg Pharma granted significant POLB 001 patent in United States

Poolbeg Pharma plc (LON:POLB, OTCQB:POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that, further to its announcement on 20 March 2024, the Company has received the fully granted